Efficacy of an infant formula manufactured ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Efficacy of an infant formula manufactured from a specific protein hydrolysate derived from whey protein isolate and concentrate produced by Société des Produits Nestlé S.A. in reducing the risk of developing atopic dermatitis.
Auteur(s) :
Castenmiller, J. [Auteur]
European Food Safety Authority [EFSA]
Hirsch-Ernst, K. I. [Auteur]
Kearney, J. [Auteur]
Knutsen, H. K. [Auteur]
Maciuk, A. [Auteur]
Mangelsdorf, I. [Auteur]
Mcardle, H. J. [Auteur]
Naska, A. [Auteur]
Pelaez, C. [Auteur]
Pentieva, K. [Auteur]
Siani, A. [Auteur]
Thies, F. [Auteur]
Tsabouri, S. [Auteur]
Turck, Dominique [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Vinceti, M. [Auteur]
Marchelli, R. [Auteur]
Van Loveren, H. [Auteur]
Dumas, C. [Auteur]
Titz, A. [Auteur]
De Henauw, S. [Auteur]
European Food Safety Authority [EFSA]
Hirsch-Ernst, K. I. [Auteur]
Kearney, J. [Auteur]
Knutsen, H. K. [Auteur]
Maciuk, A. [Auteur]
Mangelsdorf, I. [Auteur]
Mcardle, H. J. [Auteur]
Naska, A. [Auteur]
Pelaez, C. [Auteur]
Pentieva, K. [Auteur]
Siani, A. [Auteur]
Thies, F. [Auteur]
Tsabouri, S. [Auteur]
Turck, Dominique [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Vinceti, M. [Auteur]
Marchelli, R. [Auteur]
Van Loveren, H. [Auteur]
Dumas, C. [Auteur]
Titz, A. [Auteur]
De Henauw, S. [Auteur]
Titre de la revue :
EFSA Journal
Nom court de la revue :
EFSA J
Numéro :
19
Pagination :
e06603
Date de publication :
2021-07-03
ISSN :
1831-4732
Mot(s)-clé(s) en anglais :
protein hydrolysate
characterisation
formula
allergy
atopic dermatitis
clinical trial
infants
characterisation
formula
allergy
atopic dermatitis
clinical trial
infants
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The European Commission asked EFSA to evaluate the efficacy of an infant formula, containing aspecific protein hydrolysate derived from whey protein isolate and concentrate and manufactured bySoci et e des Produits Nestl ...
Lire la suite >The European Commission asked EFSA to evaluate the efficacy of an infant formula, containing aspecific protein hydrolysate derived from whey protein isolate and concentrate and manufactured bySoci et e des Produits Nestl e S.A., in reducing the risk of developing atopic dermatitis in infants with afamily history of allergy. This was following the submission of a dossier by Soci et e des Produits Nestl eS.A. to the European Commission, in the context of Regulation (EU) 2016/127. The protein hydrolysatefrom which the infant formula is produced is included in Annex I and II of Commission delegatedRegulation (EU) 2016/127 as suitable protein source for the manufacture of infant and follow-onformulae. This opinion does not cover the assessment of the nutritional safety and suitability of theinfant formula or the safety of the food enzymes used in the manufacture of the protein hydrolysate.The Panel considers that, in relation to the effect that is claimed, the infant formula under evaluation isnot sufficiently characterised with respect to the molecular weight distribution of peptides. From thehuman intervention studies submitted, no conclusions could be drawn on the efficacy of the infantformula in reducing the risk of developing atopic dermatitis. The Panel concludes that a cause-and-effect relationship has not been established between the consumption of the infant formula underevaluation and the reduction in the risk of developing atopic dermatitis in infants with a family historyof allergyLire moins >
Lire la suite >The European Commission asked EFSA to evaluate the efficacy of an infant formula, containing aspecific protein hydrolysate derived from whey protein isolate and concentrate and manufactured bySoci et e des Produits Nestl e S.A., in reducing the risk of developing atopic dermatitis in infants with afamily history of allergy. This was following the submission of a dossier by Soci et e des Produits Nestl eS.A. to the European Commission, in the context of Regulation (EU) 2016/127. The protein hydrolysatefrom which the infant formula is produced is included in Annex I and II of Commission delegatedRegulation (EU) 2016/127 as suitable protein source for the manufacture of infant and follow-onformulae. This opinion does not cover the assessment of the nutritional safety and suitability of theinfant formula or the safety of the food enzymes used in the manufacture of the protein hydrolysate.The Panel considers that, in relation to the effect that is claimed, the infant formula under evaluation isnot sufficiently characterised with respect to the molecular weight distribution of peptides. From thehuman intervention studies submitted, no conclusions could be drawn on the efficacy of the infantformula in reducing the risk of developing atopic dermatitis. The Panel concludes that a cause-and-effect relationship has not been established between the consumption of the infant formula underevaluation and the reduction in the risk of developing atopic dermatitis in infants with a family historyof allergyLire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-01-12T06:41:32Z
2024-03-01T10:55:56Z
2024-03-01T10:55:56Z
Fichiers
- EFSA Journal - 2021 - - Efficacy of an infant formula manufactured from a specific protein hydrolysate derived from whey.pdf
- Version éditeur
- Accès libre
- Accéder au document